Amgen has announced Phase III trial results have confirmed that Vectibix (panitumumab) combined with Folfiri, an irinotecan-based chemotherapy, significantly improved progression-free survival for patients with metastatic colorectal cancer (mCRC).

The trial showed that the addition of Vectibix to Folfiri significantly improved survival in patients with KRAS wild-type mCRC.

The addition of Vectibix also resulted in more than a three-fold improvement in response rate in the KRAS wild-type patient population as measured by a blinded central review.

University Hospital Ghent coordinator of the Digestive Oncology Unit Marc Peeters said that Vectibix delayed disease progression by more than half compared to Folfiri alone in patients.

“The response rate seen in this trial is among the highest ever reported in the second-line mCRC setting,” Peeters said.

No differences were reported in progression-free survival, overall survival and response rates among patients with mutated KRAS who received Vectibix.